October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
August 2023 in “Clinical and Experimental Dermatology” The document discusses a special exam case for formulating and using systemic therapy named Athena.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
9 citations
,
January 2007 in “Journal of dermatological treatment” Testosterone gel helps increase facial hair in young men with beta-thalassemia major.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
September 2024 in “Egyptian Journal of Dermatology and Venerology” Combining TRA and latanoprost is most effective for treating localized alopecia areata.
Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.
14 citations
,
January 2014 in “Journal of Cutaneous and Aesthetic Surgery” Scalp Roller therapy helped improve hair growth in patients with hard-to-treat alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Squaric acid dibutylester helps hair growth by increasing certain immune cells in the skin.
1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
June 2023 in “British Journal of Dermatology” The prototype for analyzing skin aging works technically and clinically.
August 2025 in “Australasian Journal of Dermatology” Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Traditional treatment for pediatric alopecia areata is most effective and should be first choice.
3 citations
,
September 2022 in “Archives of dermatological research” The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
August 2025 in “BMJ Open” Combining scalp acupoint catgut embedding with 5% minoxidil may help treat male pattern baldness.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
6 citations
,
April 2021 in “Patient Preference and Adherence” Patients with non-small-cell lung cancer need significant survival gains to accept severe side effects.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
66 citations
,
July 2003 in “International Journal of Dermatology” Betamethasone valerate foam is more effective and safe for treating mild-to-moderate alopecia areata than betamethasone dipropionate lotion.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
November 2006 in “評価・診断に関するシンポジウム講演論文集” KSR1 is crucial for certain skin tumor formation and could be a cancer therapy target.